Imatinib Recruiting Phase 3 Trials for Resected Gastrointestinal Stromal Tumors / KIT + / High Risk of Recurrence / Gastrointestinal Stromal Tumors / Non-metastatic / KIT Gene Mutation Prevention

IndicationsStatusPurposePhase
RecruitingPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT02260505Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)